Skip to main content
. 2019 Aug 21;39(11):1343–1357. doi: 10.1177/0333102419864132

Figure 2.

Figure 2.

Flow of study participants.

aIn the safety population, common adverse events leading to discontinuation (>1%) in the lasmiditan 100 mg group included dizziness (26 patients) and somnolence (14 patients) and in the 200 mg group included dizziness (44 patients), paresthesia (19 patients), fatigue (17 patients), nausea (13 patients), and somnolence (11 patients).